Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

1996 • 2,541 citations

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

1991 • 868 citations

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1990 • 670 citations

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

1988 • 509 citations

Chemotherapy of Lung Cancer

1992 • 434 citations

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

1994 • 376 citations

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

1994 • 364 citations

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

1986 • 337 citations

Synergistic interaction between cisplatin and gemcitabine in vitro.

1996 • 304 citations

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

1994 • 229 citations

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.

1997 • 185 citations

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.

1993 • 131 citations

Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)

1995 • 85 citations

A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

1990 • 52 citations

Studies on the mechanism of the synergistic interaction between 2?-deoxy-5-azacytidine and cisplatin

1992 • 18 citations

1079 Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study

1995 • 16 citations

PHASE I/II STUDY OF GEMCITABINE, AN ACTIVE AGENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

1995 • 13 citations